Clovis Stumbles, AstraZeneca Leads Cancer Drug Race

By | November 16, 2015

Scalper1 News

Biotech Clovis Oncology (CLVS) plummeted to a two-year low in early trading Monday after the FDA said it wanted more data showing its cancer drug candidate worked before approving it. Meanwhile, major pharma AstraZeneca (AZN) rose after its competing drug won approval three months ahead of schedule. Both Clovis’ drug rociletinib and AstraZeneca’s Tagrisso (osimertinib) target a subgroup of lung-cancer patients with epidermal growth factor Scalper1 News

Scalper1 News